StockNews.com launched coverage on the shares of ENT Intersection (NASDAQ:XENT – Get Assessment) in a report released Wednesday. The brokerage has set a “sell” rating on the medical equipment supplier’s stock.
NASDAQ XENT shares opened at $28.24 on Wednesday. The stock’s 50-day moving average is $27.93 and its two-hundred-day moving average is $27.47. The company has a debt ratio of 6.89, a current ratio of 1.88 and a quick ratio of 1.50. Intersect ENT has a 1-year minimum of $15.92 and a 1-year maximum of $28.25. The company has a market capitalization of $954.91 million, a price-earnings ratio of -5.90 and a beta of 1.45.
Intersect ENT (NASDAQ:XENT – Get Rating) last released its quarterly results on Tuesday, March 8. The medical equipment supplier reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.40). Intersect ENT recorded a negative return on equity of 709.52% and a negative net margin of 161.94%. The company posted revenue of $30.67 million for the quarter, compared to $37.43 million expected by analysts. Equity research analysts expect Intersect ENT to post -1.46 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently changed their holdings in the company. Two Sigma Investments LP increased its holdings of Intersect ENT shares by 0.5% in Q3. Two Sigma Investments LP now owns 84,300 shares of the medical equipment supplier valued at $2,293,000 after acquiring 401 additional shares in the last quarter. Guggenheim Capital LLC increased its equity stake in Intersect ENT by 1.1% in Q1. Guggenheim Capital LLC now owns 39,091 shares of the medical equipment supplier valued at $1,095,000 after acquiring 435 additional shares in the last quarter. Wolverine Asset Management LLC increased its holdings of Intersect ENT shares by 6.6% in Q4. Wolverine Asset Management LLC now owns 8,850 shares of the medical equipment supplier valued at $241,000 after acquiring an additional 550 shares in the last quarter. Royal Bank of Canada increased its holdings of Intersect ENT shares by 6.8% in the second quarter. Royal Bank of Canada now owns 8,780 shares of the medical equipment supplier valued at $150,000 after acquiring 558 additional shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in Intersect ENT shares by 1.4% in the 4th quarter. California State Teachers Retirement System now owns 44,738 shares of the medical equipment supplier valued at $1,222,000 after acquiring 601 additional shares in the last quarter. Institutional investors hold 92.47% of the company’s shares.
About Intersect ENT (Get a rating)
Intersect ENT, Inc operates as an ENT medical technology company in the United States. The company offers PROPEL, a steroid-releasing implant to open the surgically enlarged sinus; PROPEL Mini, a release implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid-releasing implant for the treatment of ostia or openings of the frontal and maxillary sinuses of dependent sinuses.
Get news and reviews for Intersect ENT Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Intersect ENT and related companies with MarketBeat.com’s free daily email newsletter.